Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients
with recurrent transitional cell bladder cancer.